A small-molecule antivirulence agent for treating Clostridium difficile infection
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A small-molecule antivirulence agent for treating
Clostridium difficile
infection
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 7, Issue 306, Pages 306ra148-306ra148
Publisher
American Association for the Advancement of Science (AAAS)
Online
2015-09-24
DOI
10.1126/scitranslmed.aac9103
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small Molecule Inhibitors of Clostridium difficile Toxin B-Induced Cellular Damage
- (2015) John Tam et al. CHEMISTRY & BIOLOGY
- Burden of Clostridium difficile Infection in the United States
- (2015) Fernanda C. Lessa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
- (2014) Zhiyong Yang et al. INFECTION AND IMMUNITY
- Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis
- (2014) Shan Li et al. INFECTION AND IMMUNITY
- A New Type of Toxin A-Negative, Toxin B-Positive Clostridium difficile Strain Lacking a CompletetcdAGene
- (2014) Sandra Janezic et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways
- (2014) Gajendra Kumar Azad et al. MOLECULAR BIOLOGY REPORTS
- Fecal microbiota transplantation: effectiveness, complexities and lingering concerns
- (2014) E G Pamer Mucosal Immunology
- Harnessing Microbiota to Kill a Pathogen: Fixing the microbiota to treat Clostridium difficile infections
- (2014) Ying Taur et al. NATURE MEDICINE
- Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore
- (2014) Z. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics
- (2014) Pedro F. Vale et al. PLOS BIOLOGY
- High-Throughput Screening Using the Differential Radial Capillary Action of Ligand Assay Identifies Ebselen As an Inhibitor of Diguanylate Cyclases
- (2013) Ori J. Lieberman et al. ACS Chemical Biology
- Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections
- (2013) Christina M Surawicz et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Overview of Severe Clostridium difficile Infection
- (2013) Stephen R. Eaton et al. CRITICAL CARE CLINICS
- Therapy ofClostridium difficileinfection: perspectives on a changing paradigm
- (2013) Mai-Chi N Tran et al. EXPERT OPINION ON PHARMACOTHERAPY
- Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens
- (2013) Katharine M. Ng et al. NATURE
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
- (2013) Els van Nood et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex
- (2013) M. A. Farrow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen
- (2013) Lorenza Favrot et al. Nature Communications
- Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB
- (2013) Jordi M. Lanis et al. PLoS Pathogens
- Burden of Clostridium difficile on the Healthcare System
- (2012) Erik R. Dubberke et al. CLINICAL INFECTIOUS DISEASES
- Can we identify patients at high risk of recurrent Clostridium difficile infection?
- (2012) C.P. Kelly CLINICAL MICROBIOLOGY AND INFECTION
- The rise of the Enterococcus: beyond vancomycin resistance
- (2012) Cesar A. Arias et al. NATURE REVIEWS MICROBIOLOGY
- Clostridium difficile Toxin B Causes Epithelial Cell Necrosis through an Autoprocessing-Independent Mechanism
- (2012) Nicole M. Chumbler et al. PLoS Pathogens
- Toward a structural understanding of Clostridium difficile toxins A and B
- (2012) Rory N. Pruitt et al. Frontiers in Cellular and Infection Microbiology
- Cytotoxicity ofClostridium difficiletoxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol
- (2012) Shan Li et al. Pathogens and Disease
- Protection from Clostridium difficile toxin B-catalysed Rac1/Cdc42 glucosylation by tauroursodeoxycholic acid-induced Rac1/Cdc42 phosphorylation
- (2011) Vanessa Brandes et al. BIOLOGICAL CHEMISTRY
- New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia
- (2011) B. Elliott et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins
- (2011) Aimee Shen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Mimics of Glutathione Peroxidase: Bioinspired Synthetic Antioxidants
- (2010) Krishna P. Bhabak et al. ACCOUNTS OF CHEMICAL RESEARCH
- Rational Design of Inhibitors and Activity-Based Probes Targeting Clostridium difficile Virulence Factor TcdB
- (2010) Aaron W. Puri et al. CHEMISTRY & BIOLOGY
- Murine Model ofClostridium difficileInfection with Aged Gnotobiotic C57BL/6 Mice and a BI/NAP1 Strain
- (2010) S. W. Pawlowski et al. JOURNAL OF INFECTIOUS DISEASES
- Chemoenzymatic synthesis of organoselenium(IV) compounds and their evaluation as cysteine protease inhibitors
- (2010) Leandro Piovan et al. JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY
- A toxin contest
- (2010) Jimmy D. Ballard NATURE
- The role of toxin A and toxin B in Clostridium difficile infection
- (2010) Sarah A. Kuehne et al. NATURE
- Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A
- (2010) Isa Kreimeyer et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Treatment with Monoclonal Antibodies againstClostridium difficileToxins
- (2010) Israel Lowy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain
- (2009) Jennifer R. O'Connor et al. GASTROENTEROLOGY
- Secular Trends of Hospitalization With Vancomycin-Resistant Enterococcus Infection in the United States, 2000–2006
- (2009) Andrew M. Ramsey et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Structure-Function Analysis of Inositol Hexakisphosphate-induced Autoprocessing inClostridium difficileToxin A
- (2009) Rory N. Pruitt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Toxin B is essential for virulence of Clostridium difficile
- (2009) Dena Lyras et al. NATURE
- Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease
- (2008) W. N. Al-Nassir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium
- (2008) Guilin Yang et al. BMC MICROBIOLOGY
- A Mouse Model of Clostridium difficile–Associated Disease
- (2008) Xinhua Chen et al. GASTROENTEROLOGY
- Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection
- (2008) Mary Y. Hu et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started